Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed ...

Lexicon Pharmaceuticals ... the FDA did not change the PDUFA date for Zynquista. Shares of the company were up 13.7% on Aug ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company leveraging advanced genetic research to develop transformative medicines, particularly for diabetes and related conditions.

Stay informed and make judicious decisions using our Ratings Table. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization ...

Lexicon Pharmaceuticals received a complete ... was expected and aligns with the pharmaceutical company's previously disclosed decision to discontinue the treatment and focus solely on its ...

Lexicon Pharmaceuticals ... a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The ...